Brokerages Set Health Catalyst, Inc. (NASDAQ:HCAT) PT at $11.45

Shares of Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $11.45.

A number of equities research analysts recently issued reports on HCAT shares. Stephens increased their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an "equal weight" rating in a research report on Thursday, November 14th. KeyCorp raised shares of Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 price objective for the company in a report on Wednesday, January 8th. Evercore ISI boosted their target price on Health Catalyst from $8.00 to $10.00 and gave the stock an "outperform" rating in a report on Tuesday, October 8th. Royal Bank of Canada increased their price target on Health Catalyst from $8.00 to $9.00 and gave the stock a "sector perform" rating in a research report on Thursday, November 7th. Finally, Citigroup cut their price objective on Health Catalyst from $10.50 to $10.00 and set a "buy" rating for the company in a research report on Friday.

Health Catalyst Price Performance

HCAT traded down $0.59 during midday trading on Tuesday, reaching $5.90. 1,107,678 shares of the company's stock were exchanged, compared to its average volume of 634,673. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The business has a 50-day simple moving average of $7.77 and a two-hundred day simple moving average of $7.55. The firm has a market capitalization of $359.00 million, a price-to-earnings ratio of -4.37 and a beta of 1.36. Health Catalyst has a one year low of $5.42 and a one year high of $11.06.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. During the same quarter last year, the business earned ($0.22) EPS. Health Catalyst's quarterly revenue was up 3.5% compared to the same quarter last year. As a group, research analysts predict that Health Catalyst will post -0.33 EPS for the current year.

Insider Transactions at Health Catalyst

In other news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total transaction of $40,109.30. Following the transaction, the chief operating officer now directly owns 129,690 shares of the company's stock, valued at $998,613. This trade represents a 3.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Benjamin Landry sold 19,268 shares of the company's stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.32, for a total transaction of $160,309.76. Following the completion of the sale, the general counsel now owns 72,250 shares of the company's stock, valued at approximately $601,120. This represents a 21.05 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 74,727 shares of company stock worth $601,810 in the last quarter. 2.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quest Partners LLC acquired a new stake in shares of Health Catalyst in the 3rd quarter valued at about $34,000. Quarry LP raised its position in Health Catalyst by 59.4% in the 2nd quarter. Quarry LP now owns 7,002 shares of the company's stock valued at $45,000 after buying an additional 2,610 shares during the last quarter. nVerses Capital LLC acquired a new position in Health Catalyst during the 3rd quarter worth approximately $59,000. Quadrature Capital Ltd bought a new position in shares of Health Catalyst during the 3rd quarter worth approximately $84,000. Finally, Mackenzie Financial Corp acquired a new stake in shares of Health Catalyst in the second quarter valued at approximately $70,000. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.